Abeona Therapeutics (ABEO) EBITDA Margin (2011 - 2026)

Abeona Therapeutics' EBITDA Margin history runs 13 years deep, the most recent figure standing at 197.64% for Q1 2026.

• In Q1 2026, EBITDA Margin changed N/A year-over-year to 197.64%; the TTM figure through Mar 2026 stood at 455.18% (changed N/A YoY), while the FY2025 annual figure was 1225.31%, changed N/A from the prior year.
• EBITDA Margin was 197.64% for Q1 2026 at Abeona Therapeutics, up from 375.13% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 27213.75% in Q2 2025 to a low of 10597.06% in Q4 2022.
• Historically, EBITDA Margin has averaged 1201.0% across 4 years, with a median of 476.69% in 2023.
• Biggest YoY gain for EBITDA Margin was 31161 bps in 2023; the steepest drop was 31161 bps in 2023.
• A 4-year view of EBITDA Margin shows it stood at 10597.06% in 2022, then soared by 96 bps to 476.69% in 2023, then grew by 21 bps to 375.13% in 2025, then jumped by 47 bps to 197.64% in 2026.
• The last three EBITDA Margin figures came in at 197.64% (Q1 2026), 375.13% (Q4 2025), and 27213.75% (Q2 2025), per Business Quant data.